Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 13/20 | 0.60 |
| ▸ | ABL1 | P00519 | 7/20 | 0.53 |
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.53 |
| ▸ | FYN | P06241 | 2/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.53 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.53 |
| ▸ | HCK | P08631 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | YES1 | P07947 | 1/20 | 0.53 |
| ▸ | LYN | P07948 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | FGR | P09769 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | PRKACA | P17612 | 1/20 | 0.53 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13019879 | 0.87 | SRC (0.58) | SRCABL1EGFRRIPK2FYN | |
| SCHEMBL13019906 | 0.87 | SRC (0.56) | SRCABL1EGFRRIPK2FYN | |
| SCHEMBL13019876 | 0.87 | SRC (0.63) | SRCABL1EGFRRIPK2FYN | |
| SCHEMBL13019900 | 0.86 | SRC (0.50) | SRCABL1EGFRRIPK2FYN | |
| SCHEMBL13019923 | 0.86 | KDM4E (0.53) | SRCABL1EGFRRIPK2FYN | |
| SCHEMBL13019878 | 0.86 | SRC (0.64) | SRCABL1EGFRRIPK2FYN | |
| SCHEMBL3779332 | 0.86 | SRC (0.62) | SRCABL1EGFRRIPK2FYN | |
| SCHEMBL13019908 | 0.85 | SRC (0.60) | SRCABL1EGFRRIPK2FYN | |
| SCHEMBL13019886 | 0.84 | SRC (0.51) | SRCABL1EGFRRIPK2FYN | |
| SCHEMBL13019912 | 0.84 | MAPT (0.52) | SRCABL1EGFRRIPK2FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3430017-B1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | UNIV CALIFORNIA (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3430017-B1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | UNIV CALIFORNIA (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-09-17 | — | — | US | disclosed |
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-09-17 | — | — | US | disclosed |
| EP-3430017-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | The Regents of The University of California (US) | 2019-01-23 | — | — | EP | disclosed |
| WO-2017161344-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | THE REGANTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017161344-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | THE REGANTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2217239-A2 | MODULATION OF PROTEIN TRAFFICKING | Foldrx Pharmaceuticals, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009062118-A2 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | LIPA, LSS, LIPC | SRC 1524/4885ABL1 283/4885EGFR 4811/4885 |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | LIPA, LSS, LIPC | SRC 1524/4885ABL1 283/4885EGFR 4811/4885 |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | SRC 1332/4885ABL1 1725/4885EGFR 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.